Clinical Research Directory

Inclusion Criteria: To be eligible, patients must meet the same criteria as those of the general SNAP platform, as well as the domain-specific criteria: * Microbiological isolation: Presence of Staphylococcus aureus complex in at least one blood culture. * Hospitalization status: The patient must be admitted to a participating hospital at the time of eligibility assessment. * Time window: Eligibility assessment must be completed within 72 hours after collection of the initial blood culture. Exclusion Criteria: General Medical and Safety Factors: * Allergies: Known hypersensitivity to thienopyridines (clopidogrel, prasugrel, ticlopidine). * Clinical status: Inability to tolerate or take oral medications, and severe hepatic impairment (Child-Pugh Class C). * Pregnancy: Pregnant or breastfeeding women. High Risk of Bleeding or Hematologic Disorders: * Active or recent bleeding: Significant bleeding or invasive procedures within the previous 7 days. * Planned surgeries: Requirement for major surgical intervention within 10 days following study enrollment. * Coagulation parameters: Platelet count \<50,000/mm³ or known coagulation disorders. * Concomitant medications: Patients already receiving regular aspirin therapy, other P2Y12 inhibitors, or therapeutic-dose anticoagulants (prophylactic-dose heparin is permitted). Specific Diagnoses and Clinical Criteria: * Endocarditis: Confirmed diagnosis or clinical suspicion of bacterial endocarditis. Sources indicate that exclusion of endocarditis is justified because the potential benefit of clopidogrel is expected during early phases of high bacterial burden, whereas bleeding risk increases with prolonged treatment or established deep-seated infections. * Medical judgment: If the treating clinical team determines that participation in this domain is not in the patient's best interest.